Cipro is a second-generation quinolone and prior to the availability of Levaquin, Cipro was the most frequently prescribed antibiotic for the initial symptoms of prostatitis. The drug comes in 250, 500 or 750 mg tablet forms, 5% or 10% oral solution and 200 mg or 400 mg vials for intravenous administration. For adults the usually prescribed dose is 500 mg twice daily for two to four weeks. Caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. Acute Uncomplicated Cystitis in females Caused by Escherichia coli or Staphylococcus saprophyticus Chronic Bacterial Prostatitis Caused by Escherichia coli or Proteus mirabilis In addition to the above listed indications Cipro has been used in a wide variety of skin, bone, joint, intra-abdominal infections with sensitive bacteria. Before the availability of drugs with fewer side effects Cipro was used for uncomplicated cervical and urethral gonorrhea. The most frequently reported drug related events from clinical trials were nausea (2.5%), diarrhea (1.6%), liver function tests abnormalities (1.3%), vomiting (1%), and rash (1%). In the great majority of the initial infections ushering in acute or chronic prostatitis, urethral and bladder symptoms are dominating. This includes bone and joint infections, intra abdominal infections, certain type of infectious diarrhea, respiratory tract infections, skin infections, typhoid fever, and urinary tract infections, among others. Ciprofloxacin is used to treat a wide variety of infections, including infections of bones and joints, endocarditis, gastroenteritis, malignant otitis externa, respiratory tract infections, cellulitis, urinary tract infections, prostatitis, anthrax, and chancroid. Ciprofloxacin only treats bacterial infections; it does not treat viral infections such as the common cold. For certain uses including acute sinusitis, lower respiratory tract infections and uncomplicated gonorrhea, ciprofloxacin is not considered a first-line agent. Ciprofloxacin occupies an important role in treatment guidelines issued by major medical societies for the treatment of serious infections, especially those likely to be caused by Gram-negative bacteria, including Pseudomonas aeruginosa. For example, ciprofloxacin in combination with metronidazole is one of several first-line antibiotic regimens recommended by the Infectious Diseases Society of America for the treatment of community-acquired abdominal infections in adults. In other cases, treatment guidelines are more restrictive, recommending in most cases that older, narrower-spectrum drugs be used as first-line therapy for less severe infections to minimize fluoroquinolone-resistance development.
Ciprofloxacin is used to treat a wide variety of bacterial infections, including infections of bones and joints, endocarditis, gastroenteritis, malignant otitis externa, respiratory tract infections, cellulitis, urinary tract infections, prostatitis, anthrax, and chancroid. Ciprofloxacin is a fluoroquinolone flor-o-KWIN-o-lone antibiotic that fights bacteria in the body. It is used to treat different types of bacterial infections, including skin infections, bone and joint infections, respiratory or sinus infections, urinary tract infections, and certain types of diarrhea.